VKTX - CIK 0001607678
The table below shows Viking Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $118.12M | $100.38M | $33.88M | $37.94M | $50.35M | $43.91M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $608.21M |
| $738.70M |
| $827.02M |
| $866.02M |
| $936.65M |
| $945.72M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $608.24M | $739.41M | $827.85M | $866.99M | $937.89M | $946.84M |
| Accounts payable | $67.18M | $4.41M | $5.49M | $7.70M | $254.00K | $11.09M |
| Total current liabilities | $106.33M | $26.07M | $31.98M | $19.57M | $25.68M | $25.09M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $106.33M | $26.39M | $32.39M | $20.07M | $26.44M | $25.86M |
| Retained earnings | -$1.01B | -$689.88M | -$599.10M | -$533.54M | -$452.49M | -$427.55M |
| Total equity | $501.92M | $713.03M | $795.46M | $846.92M | $911.45M | $920.98M |